Late breaking abstract L19 Study on the efficacy & safety of Emapalumab in treating Macrophage Activation Syndrome (
Tweet Content
Late breaking abstract L19
Study on the efficacy & safety of Emapalumab in treating Macrophage Activation Syndrome (MAS) in Still's Disease.
Key findings:
- 53.8% achieved complete response (CR) at Week 8; 85% at any time.
- Rapid reduction in hyperinflammation biomarkers… https://t.co/VcmUdRP6PV https://t.co/r7AMt0IjYk
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off